Secure core resources and technologies for developing vaccines to promote self-sufficiency of vaccines

• Secure core technologies of developing vaccines fast for national security in the event of an infectious disease disaster
• Secure various vaccine candidates to vitalize domestic vaccine development led by the government

Secure the capability of developing public vaccines for public safety and health

• Secure the capability of developing public vaccines that require urgent self-sufficiency, then lead the development of top-priority vaccines
• Support cooperation in the development of the second-priority vaccine that the private sector is reluctant to develop

• Top Priority vaccine: 3rd generation smallpox, tuberculosis for adolescents and adults, SFTS, pandemic infectious diseases, etc.
• 2nd priority vaccine: mumps, Japanese encephalitis, hepatitis A, hand-foot-and-mouth disease, whooping cough, infectious disease designated by WHO, unsolved infectious disease, etc.
• WHO 10 NEXT Infectious Diseases: Marburg disease, Rift Valley Fever, Ebola, Crimean Congo Hemorrhagic Fever, Monkey Smallpox, Lassa fever, Nipah Virus, SARS, MERS, Zika

Support for facilities and efficacy evaluation system to promote vaccine R&D and commercialization

• Provide infrastructure such as “effectiveness evaluation service for vaccines under development” and high-risk biosafety facilities which can secure competitiveness by evaluating and guaranteeing the effectiveness of vaccine candidates

Propose the direction of policies through taking the role of control tower on public vaccine R&D

• Perform the role of a control tower for developing vaccines and its commercialization through cooperation between the government (Ministry of Health and Welfare, Ministry of Food and Drug Safety, Ministry of Industry, etc.) and the private sector
• Link and support the industry so that vaccine materials secured through the R&D can be actually produced.